Recommendations for surveillance of Clostridium difficile-associated disease

被引:471
|
作者
McDonald, L. Clifford
Coignard, Bruno
Dubberke, Erik
Song, Xiaoyan
Horan, Teresa
Kutty, Preeta K.
机构
[1] Ctr Dis Control & Prevent, Atlanta, GA USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
[4] Inst Veille Sanitaire, St Maurice Cedex, France
来源
关键词
D O I
10.1086/511798
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. The epidemiology of Clostridium difficile -associated disease (CDAD) is changing, with evidence of increased incidence and severity. However, the understanding of the magnitude of and reasons for this change is currently hampered by the lack of standardized surveillance methods. Objective and methods. An ad hoc C. difficile surveillance working group was formed to develop interim surveillance definitions and recommendations based on existing literature and expert opinion that can help to improve CDAD surveillance and prevention efforts. Definitions and recommendations. A CDAD case patient was defined as a patient with symptoms of diarrhea or toxic megacolon combined with a positive result of a laboratory assay and/or endoscopic or histopathologic evidence of pseudomembranous colitis. Recurrent CDAD was defined as repeated episodes within 8 weeks of each other. Severe CDAD was defined by CDAD-associated admission to an intensive care unit, colectomy, or death within 30 days after onset. Case patients were categorized by the setting in which C. difficile was likely acquired, to account for recent evidence that suggests that healthcare facility -associated CDAD may have its onset in the community up to 4 weeks after discharge. Tracking of healthcare facility -onset, healthcare facility -associated CDAD is the minimum surveillance required for healthcare settings; tracking of community-onset, healthcare facility -associated CDAD should be performed only in conjunction with tracking of healthcare facility -onset, healthcare facility -associated CDAD. Community-associated CDAD was defined by symptom onset more than 12 weeks after the last discharge from a healthcare facility. Rates of both healthcare facility -onset, healthcare facility associated CDAD and community-onset, healthcare facility -associated CDAD should be expressed as case patients per 10,000 patient-days; rates of community-associated CDAD should be expressed as case patients per 100,000 person-years.
引用
收藏
页码:140 / 145
页数:6
相关论文
共 50 条
  • [31] Clostridium difficile-associated disease in children with solid tumors
    Elio Castagnola
    Teresa Battaglia
    Roberto Bandettini
    Ilaria Caviglia
    Ivana Baldelli
    Marilina Nantron
    Cristina Moroni
    Alberto Garaventa
    Supportive Care in Cancer, 2009, 17
  • [32] Impact of Clostridium difficile-associated disease in a regional hospital
    P Dolcé
    J Blanchette
    C Ouellet
    K Levesque
    H Bernatchez
    BMC Proceedings, 5 (Suppl 6)
  • [33] Update on the changing epidemiology of Clostridium difficile-associated disease
    Lynne V McFarland
    Nature Clinical Practice Gastroenterology & Hepatology, 2008, 5 : 40 - 48
  • [34] Drug-induced Clostridium difficile-associated disease
    Job, ML
    Jacobs, NF
    DRUG SAFETY, 1997, 17 (01) : 37 - 46
  • [35] Clostridium difficile-associated infection: a disease of varying severity
    Jawa, Randeep S.
    Mercer, David W.
    AMERICAN JOURNAL OF SURGERY, 2012, 204 (06): : 836 - 842
  • [36] A Prediction Model of Disease Severity in Clostridium difficile-Associated Disease
    Im, Gene Y.
    Modayil, Rani J.
    Feuerman, Martin
    Lin, Cheng Ting
    Balani, Anil R.
    Katz, Douglas S.
    Grendell, James H.
    GASTROENTEROLOGY, 2011, 140 (05) : S361 - S361
  • [37] Metronidazole for Clostridium difficile-associated disease:: Is it okay for mom?
    Gerding, DN
    CLINICAL INFECTIOUS DISEASES, 2005, 40 (11) : 1598 - 1600
  • [38] Update on the changing epidemiology of Clostridium difficile-associated disease
    McFarland, Lynne V.
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2008, 5 (01): : 40 - 48
  • [39] Clinical impact and associated costs of Clostridium difficile-associated disease
    Spencer, RC
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 : 5 - 12
  • [40] Clostridium difficile-associated Disease in the Elderly, United States
    Jagai, Jyotsna
    Naumova, Elena
    EMERGING INFECTIOUS DISEASES, 2009, 15 (02) : 343 - 344